Search clinical trials for: Ribavirin (Copegus)

Total 835 results

Bausch Health Americas, Inc.

Completed

Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)

Chronic Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers

Healthy Volunteer

Mexico
Hoffmann-La Roche

Completed

A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets

Healthy Volunteer

United States
Conatus Pharmaceuticals Inc.

Completed

CTS-1027 in Interferon-Naive Hepatitis C Patients

Hepatitis C

United States, Puerto Rico
Karolinska Institutet
The Swedish Research Council; Hoffmann-La Roche

Completed

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment (DICO)

Chronic Hepatitis C | Human Immunodeficiency Virus

Sweden
University of Nebraska

Withdrawn

Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients

Chronic Hepatitis C

United States
Teva Pharmaceuticals USA

Completed

Ribavirin 200 mg Tablets Under Fasting Conditions

Healthy

United States
Mashhad University of Medical Sciences

Completed

Effect of Camel Milk on Chronic Hepatitis C (HCV)

Chronic Hepatitis C

Iran, Islamic Republic of
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Hepatitis C, Chronic

Brazil
Teva Pharmaceuticals USA

Completed

Ribavirin 200 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Kirby Institute

Completed

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)

Hepatitis C

Australia, New Zealand
Baqiyatallah Medical Sciences University
Shahid Beheshti University of Medical Sciences; Guilan University of Medical... and other collaborators

Completed

Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection

Hemophilia | Hepatitis C

Iran, Islamic Republic of
Hoffmann-La Roche

Withdrawn

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

Israel
Vertex Pharmaceuticals Incorporated

Completed

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Chronic Hepatitis C Virus

United States
Azienda Ospedaliera di Padova
University of Padova; Regione Veneto

Completed

Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.

Hepatitis C Virus | Chronic Liver Disease | Therapeutic Uses | Viral Hepatitis | Antiviral Agents

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients (HEPCPR)

HIV Infections | Hepatitis C

United States
Sociedad Andaluza de Enfermedades Infecciosas

Completed

Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients (SAEI_IFN_1)

HIV Infections | Hepatitis C, Chronic

Spain
Hoffmann-La Roche

Completed

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

Brazil
Merck Sharp & Dohme LLC

Completed

Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Hepatitis C, Chronic

United States, Canada
Pacific Health Foundation
Hoffmann-La Roche

Completed

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

Chronic Hepatitis C | Treatment | Asian Americans | Novel Genotypes

United States
Baqiyatallah Medical Sciences University
Guilan University of Medical Sciences; Baqiyatallah Research Center for Gastroenterology... and other collaborators

Completed

Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

Hepatitis C | Thalassemia

Iran, Islamic Republic of
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center

Terminated

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma

United States
Prof. Facchinetti Fabio
Merck Sharp & Dohme LLC

Completed

Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C (MEN_EPID)

Chronic Hepatitis C

Italy
University of Ulm
Hoffmann-La Roche

Completed

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

Liver Diseases | Virus Diseases | Hepatitis C, Chronic

Germany
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Bristol-Myers Squibb

Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Hepatitis C Infection

United States, France
University of Chicago

Withdrawn

A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

Hepatitis C | Hepatitis C Virus
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

Hepatitis C, Chronic

Sweden, New Zealand, United States, France, Brazil
Hoffmann-La Roche

Completed

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

Czech Republic
Hoffmann-La Roche

Completed

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic
Aarhus University Hospital

Completed

Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)

Hepatitis C, Chronic | Cognition Disorders | Major Depressive Disorder | Fatigue Syndrome, Chronic

Denmark
Kirby Institute
Janssen-Cilag Ltd.

Completed

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (DARE-C)

Hepatitis C, Chronic

Australia
Bristol-Myers Squibb

Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (HEPCAT)

Hepatitis C Virus

Australia, France, Mexico, United States, Canada, Germany, Denmark, Italy, Puerto Rico, Sweden, Argentina
Mayo Clinic
Roche Pharma AG

Completed

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

Hepatitis C | Liver Transplant

United States
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Hepatitis C

Austria
Debiopharm International SA

Completed

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Hepatitis C | Liver Disease

United States, France
Hoffmann-La Roche

Completed

A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)

Hepatitis D, Chronic

Italy
Hoffmann-La Roche

Completed

A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Hepatitis C, Chronic

Slovenia
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Chronic Hepatitis C Virus

United States, United Kingdom, Canada, Germany, Poland
Fundación Pública Andaluza para la gestión de la...

Completed

Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 (OPTIM)

Hepatitis C, Chronic

Spain
Charles University, Czech Republic
IGA MZ, Czech Republic

Unknown

Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection

Nonalcoholic Steatohepatitis | Chronic HCV Infection

Czech Republic
Hoffmann-La Roche

Completed

An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)

Hepatitis C, Chronic

Russian Federation, Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C

Hepatitis C, Chronic

Czechia, Slovakia
Grupo de Enfermedades Infecciosas de la Sociedad...

Unknown

Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C (Perseo)

Hepatitis C, Chronic | Personality Disorders in Prison

Spain
Foundation for Liver Research
Hoffmann-La Roche

Terminated

High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 (VIRID)

Chronic Hepatitis C

Netherlands
Casa Sollievo della Sofferenza IRCCS
University of Palermo; University of Florence; Campus Bio-Medico University; IRCCS... and other collaborators

Completed

Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) (WRITE)

Chronic Hepatitis

Italy
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Hepatitis C, Chronic

Australia, United States, Italy, France, Puerto Rico, Taiwan, United Kingdom, Greece, Poland, Brazil, Spain

3

Subscribe